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ABSTRACT
Background: γ-aminobutyric acidA (GABAA) receptors 
mediate the actions of several intravenous general anesthet-
ics. However, the contribution of α3-containing GABAA 
receptors to the action of these drugs is unknown.
Methods: The authors compared anesthetic endpoints 
(hypnosis, immobility, hypothermia) in response to various 
intravenous anesthetics in mice lacking the α3 subunit of the 
GABAA receptor (α3 knockout) and in wild-type mice. Fur-
thermore, the authors generated and analyzed conditional 
mutant mice expressing the GABAA receptor α3 subunit 
exclusively in noradrenergic neurons.
Results: α3 knockout mice displayed decreased hypnotic 
and hypothermic responses to etomidate and midazolam, 
but an increased response to pentobarbital. The hypnotic 
response to ketamine was unaltered, whereas the hypo-
thermic response was increased. In contrast, the hypnotic 
but not the hypothermic response to medetomidine was 
increased. The combination of ketamine/xylazine displayed 
increased hypnotic, immobilizing, and hypothermic effects 
in α3 knockout mice. Mice expressing the α3 subunit exclu-
sively in noradrenergic neurons were generated to assess 
whether the lack of α3 subunits on noradrenergic neurons 
may be responsible for this effect. In these mice, the increases 
of the hypnotic and immobilizing actions induced by ket-
amine/xylazine were largely absent, whereas the increase in 
the hypothermic action was still present.
Conclusion: α3-containing GABAA receptors bidirec-
tionally regulate essential anesthetic actions: they mediate 
anesthetic actions of etomidate and midazolam, known 
to selectively act at GABAA receptors, and they negatively 
constrain anesthetic actions of compounds with targets 
partly or exclusively distinct from GABAA receptors such as 
medetomidine, ketamine, and pentobarbital. Furthermore, 
our results indicate that α3-containing GABAA receptors on 
noradrenergic neurons may contribute to this constraint.
γ-AMInoButyrIc acidA (GABAA) receptors are chlo-ride channels, which mediate fast synaptic inhibition 
and tonic inhibition in the central nervous system. They are 
composed of five subunits drawn from a repertoire of eight 
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What We Already Know about This Topic
•	 The γ-aminobutyric acidA (GABAA) receptor system mediates 
actions of many general anesthetics in the central nervous 
system. However, the contributions of the different GABAA re-
ceptor subtypes and the role of noradrenergic neurons require 
further clarification
What This Article Tells Us That Is New
•	 GABAA receptors containing the α3 subunit mediate anes-
thetic responses to etomidate and midazolam. Lack of the 
α3 subunit results in enhanced responses to the combination 
ketamine/xylazine, an effect that is rescued in part by expres-
sion of the α3 subunit selectively in noradrenergic neurons, 
indicating an involvement of noradrenergic neurons in modu-
lating hypnosis
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different subunit families comprising at least 19 different 
genes (α1–6, β1–3, γ1–3, δ, ε, θ, π, ρ1–3).1–4 Depending 
on the exact subunit composition GABAA receptors possess 
different physiological and pharmacological properties.1,2 
Many general anesthetics potentiate the activity of GABAA 
receptors, and the role of several GABAA receptors sub-
types in mediating anesthetic effects has been described.3,4 
We have previously shown that β3(n265M) knock-in mice 
display dramatically reduced hypnotic responses to etomi-
date and pentobarbital and cannot be immobilized by these 
compounds, demonstrating that a subpopulation of GABAA 
receptors is essential for the anesthetic actions of these anes-
thetic agents.5 Most frequently, the GABAA receptors are 
classified by the α subunit that is present. on the basis of 
studies in global knockout (Ko) mice, the α1 subunit,6 but 
not the α57 and α6 subunits,8 contribute to the hypnotic 
actions of intravenous general anesthetics. However, the sig-
nificance of α3 subunit–containing GABAA receptors for 
anesthetic effects remained to be clarified.
Performing stereotaxic surgeries we made the unexpected 
and surprising observation that a combination of ketamine, 
an N-methyl-D-aspartate receptor antagonist and xylazine, an 
α2-adrenergic agonist, induces remarkably prolonged anes-
thesia in α3Ko mice compared with wild-type (Wt) mice. 
The α3 subunit of the GABAA receptor is present in 10–15% 
of all GABAA receptors in the central nervous system and 
GABAA receptors containing the α3 subunit are expressed 
widely in the brain.1,2 However, in monoaminergic neurons 
the α3 subunit seems to be the major α subunit expressed. 
High expression levels in noradrenergic neurons9–11 suggest 
that α3 subunit–containing GABAA receptors might be 
important modulators of the noradrenergic system.
The noradrenergic system (cell groups A1–A10), which 
includes the locus coeruleus (A6) whose neurons project 
widely throughout the neuraxis and other noradrenergic 
nuclei (e.g., A1 and A2, which project mainly to the hypo-
thalamus) plays an important role in the regulation of sleep 
and arousal as well as thermoregulation.12–14 Activity of the 
noradrenaline-containing locus coeruleus neurons depends 
on the behavioral state (e.g., sleeping or waking) of the organ-
ism and this system is likely involved in switching between 
these different states.15 Moreover, α2-adrenoceptor agonists 
such as dexmedetomidine have been shown to exert their sed-
ative/hypnotic effects through endogenous sleep pathways,16 
at least in part through inhibition of the locus coeruleus.17
In order to obtain insights into the role of α3-
containing GABAA receptors in general anesthetic actions, 
we investigated (1) in α3Ko mice whether α3-containing 
GABAA receptors mediate the action of intravenous 
general anesthetics known to act at least in part via GABAA 
receptors such as etomidate, midazolam, and pentobarbital; 
(2) whether α3-containing GABAA receptors play a role in 
the actions of the N-methyl-D-aspartate receptor antagonist 
ketamine and of the α2-adrenergic agonist medetomidine, 
either alone or in combination, using α3Ko mice; and (3) 
whether α3-containing GABAA receptors on noradrenergic 
neurons are responsible for the increased sensitivity to 
ketamine/xylazine. to this end, using conditional cre-loxP-
mediated recombination limited to noradrenergic neurons, 
we generated α3Ko mice in which the α3 subunit was 
reintroduced exclusively in noradrenergic neurons.
Materials and Methods
Animals
Male mice on the c57BL/6J background between 8 and 18 
weeks of age at beginning of experiments were used. Biochem-
ical and morphological studies were performed in Zurich 
(Switzerland) with approval of the cantonal Veterinary office 
of Zurich and performed in accordance with international 
guidelines on animal use and care (European community 
council Directive 86⁄609⁄EEc). All behavioral experiments 
were conducted in Belmont in accordance with the national 
Institutes of Health guide for the care and use of Labora-
tory Animals, and were approved by the McLean Hospital 
Institutional Animal care and use committee, Belmont, 
Massachusetts. Mice lacking the α3 subunit of the GABAA 
receptor (α3Ko mice) have been described previously.18 For 
behavioral testing mice were group-housed (3–4 per cage) and 
kept under a reversed 12/12 h light–dark cycle (lights on from 
9:00 PM to 9:00 AM) for at least 2 weeks before beginning of 
experimental testing and throughout the study.
Generation of Global Rescue Mice
The generation of mice lacking the α3 subunit of the GABAA 
receptor (α3Ko mice) has been described in detail.18 The 
absence of α3 messenger rnA was demonstrated by reverse 
transcription polymerase chain reaction, and the absence of 
the α3 protein by Western blot and immunohistochemistry.18 
As the nomenclature of exons in the Gabra3 gene has changed 
over time, exon 4 in the study by yee et al.18 is identical to 
exon 5 as described here. These mice carry an artificial exon 
flanked by loxP sites in the Gabra3 gene, which is located 
on the X-chromosome. In mice that carry both the mutant 
gene and express the cre recombinase this artificial exon is 
removed, thereby restoring α3 subunit expression. Mice in 
which the α3 subunit is rescued globally have been generated 
by crossing α3Ko mice with EIIa-cre mice, which express 
the cre recombinase in oocytes and preimplantation stages 
of the embryo.19 Mice carrying both the mutant gene and the 
cre recombinase gene have been selected by polymerase chain 
reaction genotyping. These mice were crossed with c57BL/6J 
Wt mice. Hemizygote male mice carrying only the mutant 
gene were then selected for experiments to ensure that the res-
cue of the α3 subunit had been present in the germline.
Generation of Neuron-specific Rescue Mice
Mice expressing the α3 subunit of the GABAA recep-
tor exclusively in noradrenergic (dopamine β hydroxy-
lase [DBH]-rescue mice) and dopaminergic (dopamine 
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transporter [DAt]-rescue mice) neurons, respectively, have 
been generated by crossing female α3Ko mice with male 
mice expressing the improved cre (icre) recombinase spe-
cifically in (nor)adrenergic (DBH-icre mice) or dopami-
nergic neurons (DAt-icre mice). DBH-icre mice express 
the icre recombinase under the control of the promoter of 
the DBH gene and have been described previously.20,21 DAt-
icre mice express the icre recombinase under the control of 
the promoter of the DAt gene and have been described pre-
viously.22 Male mice carrying both the α3Ko gene and the 
respective icre transgene have been selected by polymerase 
chain reaction genotyping.
Immunoperoxidase Staining
Four Wt and four global rescue mice (9 weeks of age) 
were deeply anaesthetized with pentobarbital (nembutal®, 
Abbott, chicago, IL; 50 mg⁄kg, intraperitoneally) and 
perfused through the ascending aorta with fixative solution 
(4% paraformaldehyde in 0.15 M phosphate buffer and 
15% saturated picric acid solution; pH 7.4). Brains were 
postfixed in fixative solution for 3 h and incubated in citrate 
buffer (0.2 M na2HPo4 dihydrate, 0.1 M citric acid; pH 4.5) 
overnight. The next day brains were cut parasagittally into 
approximately 8-mm thick blocks and irradiated in citrate 
buffer at 650 watt in the microwave for 90 s for antigen 
retrieval.23 Brains were cryoprotected in 10% dimethyl 
sulfoxide in phosphate buffered saline (PBS) for at least 
2 h before sectioning them transversally at 40 µm with a 
sliding microtome. The sections were collected in PBS. 
Free-floating sections were incubated overnight at 4°c with 
a primary antibody directed against the α3 subunit of the 
GABAA receptor (1:5,000; antibody was developed in-house 
and is described in detail)9 in tristriton buffer (0.05 M tris, 
0.15 M nacl, 0.2% triton X-100; pH 7.4) containing 2% 
normal goat serum. The next day sections were washed 
three times in tris-triton buffer and incubated for 30 min 
at room temperature in biotinylated secondary antibody 
(1:300; Jackson Immunoresearch, West Grove, PA) in tris-
triton buffer containing 2% normal goat serum. After three 
washes in tris-triton buffer, sections were incubated in the 
Avidin-Peroxidase (ABc)-Solution (1:100 in tristriton 
buffer) for 30 min (Vectastain Elite Kit; Vector Laboratories, 
Burlingame, cA) and after another wash finally reacted 
with diaminobenzidine tetrahydrochloride (Sigma-Aldrich, 
St. Louis, Mo) in tris-triton buffer (pH 7.7) containing 
0.015% hydrogen peroxide. After 15 min the color reaction 
was stopped with ice-cold PBS. After two washes in PBS 
at room temperature, sections were mounted on gelatin-
coated slides and air-dried. Finally, they were dehydrated 
with an ascending series of ethanol, cleared in xylene, 
and coverslipped with Eukitt (Erne chemie, Dällikon, 
Switzerland). Brains and sections from Wt and global rescue 
mice were processed in parallel under identical conditions to 
minimize variability in staining intensity. Images were taken 
with a stereo microscope (Zeiss, Jena, Germany).
Immunofluorescence Staining
DAt-rescue (n = 4), DBH-rescue (n = 3), Wt (n = 3), and 
α3Ko (n =2) mice (8–14 weeks of age) were examined to 
confirm selective expression of the α3 subunit in dopami-
nergic and noradrenergic neurons, respectively. For optimal 
and simultaneous detection of tyrosine hydroxylase, a neu-
ronal marker for dopaminergic and noradrenergic neurons, 
and the α3 subunit of the GABAA receptor a novel protocol 
was used, which has been described in detail previously.24,25 
In brief, mice were anesthetized with isoflurane and decapi-
tated. The brain was quickly removed and placed in ice-cold 
artificial cerebrospinal fluid (composition in mM: nacl, 125; 
naHco3, 26; naH2Po4, 1.25; Kcl, 2.5; Mgcl2, 1; cacl2, 
2.5; and glucose, 11; oxygenated with 95% o2–5% co2). 
The brain was affixed to a vibratome stage with cyanoac-
rylate and kept in the ice-cold artificial cerebrospinal fluid 
for slicing. Parasagittal 300 µm-thick slices were prepared 
and incubated at 33°c for 20 min in oxygenated artificial 
cerebrospinal fluid. They were then fixed by immersion for 
10 min in 4% paraformaldehyde in 0.15 M phosphate buffer, 
washed with PBS, cryoprotected overnight in 30% sucrose 
in PBS, and frozen on a flat surface in the cryostat. Parasagit-
tal sections were cut at a thickness of 16 µm, mounted onto 
gelatin-coated glass slides, air-dried at room temperature for 
30 s, and stored at 20°c for at least 1 h. Sections were pre-
incubated for 1 h at room temperature in PBS containing 
10% normal goat serum and 0.2% triton X-100, followed 
by overnight incubation at 4°c with primary antibodies 
against tyrosine hydroxylase raised in rabbit (1:5,000; Merck 
Millipore, Billerica, MA) and against the α3 subunit of the 
GABAA receptor raised in guinea pig (1:3,000)
9 diluted in the 
same solution. Sections were then washed extensively in PBS 
and incubated for 1 h at room temperature in correspond-
ing affinity-purified goat immunoglobulin G coupled to cy3 
(1:500) or Alexa 488 (1:1000; Jackson Immunoresearch). 
Sections were washed again, and coverslipped with aqueous 
mounting medium (Dako, carpinteria, cA). Immunofluo-
rescence staining was visualized by confocal laser scanning 
microscopy (LSM-510 Meta; Zeiss) with a 40× objective 
(n.A. 1.3) and sequential acquisition of separate color chan-
nels. Image-acquisition settings were adjusted to cover the 
entire dynamic range of the photomultipliers. The pinhole 
size was set to 1.0 Airy units for each channel, and stacks 
of 12 sections (512 × 512) spaced by 0.4 µm were acquired. 
For display, images were processed with the image-analysis 
program Imaris (Bitplane, Zurich, Switzerland). Images from 
both channels were overlaid, background was subtracted, and 
a low-pass filter (“edge preserving” filter) was applied. Images 
are displayed as extended projection of the entire stack.
Western Blotting
Membrane preparation and Western blotting have been 
conducted as described previously.26 Fresh frozen brains 
from five Wt and five global rescue mice (10 weeks of age) 
were homogenized in 5 ml sucrose buffer (0.32 M sucrose, 
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5 mM ethylenediaminetetraacetic acid, 10 mM tris pH 
7.5, 0.02% nan3, phenylmethanesulfonyl fluoride 1:500, 
complete, mini protease inhibitor cocktail [roche Diagnostics, 
Mannheim, Germany]) and centrifuged for 10 min at 1,000g. 
The supernatant was collected and the step repeated. Both 
supernatants were combined and centrifuged for 20 min at 
40,000g to obtain the crude membrane fraction. The pellet was 
resuspended in 3 ml sucrose buffer. Protein concentration was 
determined using the BcA protein assay kit (Pierce, rockford, 
IL). Samples were incubated for 5 min at 95°c with an equal 
volume of 125 mM tris-Hcl pH 6.8, 20% glycerol, 0.002% 
bromphenol blue, 10% β-mercaptoethanol, 4% sodium 
dodecyl sulfate and stored at −20°c. Before use samples were 
incubated for 10 min at 60°c and diluted to a concentration 
of 1 mg/ml. Aliquots with increasing protein content (2.5, 
5, 7.5, and 10 μg) were subjected to sodium dodecyl sulfate 
polyacrylamide gel electrophoresis using 10% minigels (Mini 
protean II; Bio-rad, Hercules, cA). Proteins were transferred 
onto nitrocellulose membranes using a trans Blot Mini cell 
(Bio-rad). The blots were blocked for 1–2 h in 10 mM tris-
Hcl pH 8, 0.15 M nacl, 0.05% tween 20 containing 5% 
nonfat dry milk at room temperature, followed by incubation 
with affinity-purified antiserum against the α3 subunit of 
the GABAA receptor (1:500)
9 together with a monoclonal 
antibody directed against β-actin (1:20,000, Merck Millipore) 
overnight at 4°c in 10 mM tris-Hcl pH 8, 0.15 M nacl, 
0.05% tween 20/5% nonfat dry milk. The blots were 
washed once with 20 mM tris pH 7.5, 60 mM nacl, 2 mM 
ethylenediaminetetraacetic acid, 0.4% SDS, 0.4% triton-X 
100, and 0.4% deoxycholate and four times with 10 mM tris-
Hcl pH 8, 0.15 M nacl, 0.05% tween 20. Incubation with 
the appropriate horseradish peroxidase-conjugated secondary 
antibodies was carried out for 1 h at room temperature. After 
extensive washing immunoreactivity was detected by the 
enhanced chemoluminescence method (Super Signal West 
Pico chemoluminescence, Pierce), images were captured using 
a Fujifilm (tokyo, Japan) LAS-1000 Plus Gel Documentation 
System, and immunoreactive bands were quantified with the 
AIDA software (Version 3.25, raytest, Pforzheim, Germany). 
Actin immunoreactivity was used to monitor equal sample 
loading. The specificity of the antibody against the α3 subunit 
has been confirmed previously using α3Ko mice.18
Drugs
Ketamine-Hcl/Xylazine-Hcl solution (Sigma-Aldrich) 
was administered at a volume of 20 ml/kg. Ketamine-Hcl 
(Sigma-Aldrich), medetomidine-Hcl solution (Domitor®, 
Pfizer Animal Health, new york, ny) and pentobarbital-na 
(Sigma-Aldrich) were administered at a volume of 10 ml/kg. 
Etomidate (Amidate®, Hospira, Lake Forest, IL) was admin-
istered at a volume of 15 ml/kg. Midazolam-Hcl solution 
(Bedford Laboratories, Bedford, oH) was administered at a 
volume of 16.5 ml/kg. All drugs were dissolved or diluted in 
physiological (0.9%) saline where necessary and drug doses 
were calculated as mg/kg base. All drugs were administered 
by intraperitoneal injection. The doses administered are 
reported in the results section.
Behavioral Testing
tests were conducted during the dark phase (9:00 AM–
9:00 PM) and each test was conducted at approximately the 
same time of day. The tester was blind to the genotype of 
the animals. Animals were tested in three cohorts. cohort 1 
containing Wt, α3Ko, DBH-rescue, and DBH-icre mice 
received a single injection of ketamine/xylazine and anesthetic 
properties were observed. cohort 2 containing Wt and 
α3Ko mice were first tested for medetomidine-induced seda-
tion in the locomotor activity test, 3 days later for medetomi-
dine-induced hypothermia, and 4–6 days later for anesthetic 
 properties of ketamine, medetomidine, or pentobarbital. Ani-
mals received increasing doses of ketamine, medetomidine, 
or pentobarbital every 7 days. Mice were counterbalanced for 
drug experience. cohort 3 containing Wt and α3Ko mice 
were first tested for anesthetic properties of midazolam and 
7 days later for anesthetic properties of etomidate.
Locomotor Activity
Animals were moved into the testing room at least 1 h before 
testing. Animals were injected with medetomidine (30 µg/kg 
or 60 µg/kg) or vehicle immediately before testing. The test-
ing apparatus consisted of four evenly illuminated (approxi-
mately 130 lux) clear plexiglas (J. Freeman, Inc., Dorchester, 
MA) boxes (41 × 41 × 31 cm) separated by white cardboard. 
Boxes were cleaned with 70% ethanol, between animals. 
Locomotor activity was recorded for 60 min using the video-
tracking system EthoVisionXt (noldus Information tech-
nology, Wageningen, The netherlands).
Medetomidine-induced Hypothermia
Animals were moved into the testing room directly before 
testing. Body temperature was determined using a tH-5 
digital thermometer (Physitemp Instruments, clifton, nJ) 
with a rEt3-Iso thermal probe for mice (inserted 2 cm deep) 
immediately before drug injection (vehicle, 60 µg/kg, 120 
µg/kg medetomidine) and 30, 60, 90, and 120 min thereaf-
ter. Mice were kept together in their home cage throughout 
the experiment.
Anesthetic Endpoints
The assessment of anesthetic end points was adapted from 
published protocols.27–29 Animals were moved into the test-
ing room directly before testing. Each animal was placed in 
a clean holding cage without bedding material immediately 
after drug injection. Body temperature was determined 
using a tH-5 digital thermometer (Physitemp Instru-
ments) with an rEt3-Iso thermal probe for mice (inserted 
2 cm deep) immediately before drug injection and every 
30 min thereafter. once the animal stopped moving it was 
turned on its back. Beginning of loss of righting reflex 
(Lorr) was defined as the time-point when the animal 
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was placed on its back. End of Lorr was defined as the 
time-point when the animal righted itself spontaneously 
from dorsal to sternal recumbency with all four extremities 
touching the ground. The time between beginning and end 
of Lorr was defined as duration of Lorr. After regain-
ing the righting reflex animals were turned on their back 
every minute and time to righting was scored: less than 2 s 
(score = 1), between 2 and 10 s (score = 2), more than 10 s 
(score = 3). Animals were defined as having fully recovered 
when they were able to right themselves three times con-
secutively within 2 s. time to recovery was defined as the 
time between beginning of Lorr and full recovery. A total 
Lorr score was calculated by adding the score values for 
every minute from beginning of Lorr until full recov-
ery. The loss of hind limb withdrawal reflex (LHWr) was 
determined every 5 min by pinching the paw firmly with 
an atraumatic forceps alternating between the left and right 
hind paw until animals regained the righting reflex. LHWr 
was defined as present if no signs of reaction to the pinch 
were observed.
Anesthetic properties of medetomidine were assessed 
using a different protocol. Animals were moved into the 
testing room directly before testing and each animal was 
placed in a clean holding cage without bedding material 
immediately after drug injection. Animals were gently rolled 
on their side 30, 60, 90, and 120 min after injection and 
time to righting defined as completely returning to the prone 
position with all four extremities touching the ground was 
noted. Lorr was defined as present if animals were not able 
to roll back to the prone position within 10 s.
Statistical Analysis
Data were analyzed using the appropriate statistical test 
(Student t test, AnoVA followed by post hoc Dunnett t 
test, AnoVA with repeated measures followed by post hoc 
t tests with Bonferroni correction) or Sheffé post hoc test. 
Hypothesis testing was two-tailed. Data for medetomidine-
induced Lorr were analyzed by fitting standard least-
squares mixed models with subject as a random effect. Drug 
dose and genotype were included as fixed effects. All effects 
were assessed by F tests based on the fitted regression models. 
This analysis was followed by post hoc Mann–Whitney u 
tests. Data are expressed as the mean ± SEM. P value less than 
0.05 was considered to be statistically significant. Statistical 
analysis was performed using the SPSS (SPSS, Inc., chicago, 
IL) and GraphPad (GraphPad Software, Inc., La Jolla, cA) 
software packages.
Results
When performing stereotaxic surgeries for implantation of 
electrodes into the medial forebrain bundle under ketamine/
xylazine (139/21 mg/kg intraperitoneally) anesthesia, we 
unexpectedly observed that using the same doses of anes-
thetics α3Ko mice were anesthetized longer than Wt mice 
(approximately 130 min compared with 80 min), prompting 
us to investigate the role of α3-containing GABAA receptors 
in the action of intravenous general anesthetics.
Anesthetic Endpoints with Etomidate, Midazolam, and 
Pentobarbital
The anesthetic effects of etomidate, midazolam and pento-
barbital, three compounds known to act at least in part via 
GABAA receptors, were assessed by determining the follow-
ing endpoints: duration of Lorr, time to recovery and total 
Lorr score as a measure of hypnosis, LHWr as a measure 
of immobility, and body temperature as a measure of hypo-
thermic effects of the drug (fig. 1 and table 1).
Etomidate
Etomidate (30 mg/kg) was less effective in α3Ko mice 
compared with Wt mice. Duration of Lorr (Wt: 
88.3 ± 4.3 min, α3Ko: 72.7 ± 5.8 min) and total Lorr score 
(Wt: 273.7 ± 10.3, α3Ko: 224.9 ± 17.5) were significantly 
decreased in α3Ko mice (unpaired t test, P = 0.0439 and P 
= 0.0263, respectively), whereas time to recovery was not dif-
ferent (Wt: 91.1 ± 4.5 min, α3Ko: 77.2 ± 5.8 min, unpaired 
t test, P = 0.0710). Anesthetic-induced decrease in body 
temperature was smaller in α3Ko mice compared with Wt 
controls (two-way AnoVA with repeated measures of time: 
significant effect of time F(2,40), P < 0.0001; significant effect 
of genotype F(1,20) = 4.90, P = 0.0386; significant time × 
genotype interaction F(2,40) = 8.12, P = 0.0011). Post hoc t 
tests with Bonferroni correction showed that the temperature 
differed significantly 90 min after injection (P < 0.01).
Midazolam
The hypnotic action of midazolam (75 mg/kg) was decreased 
in α3Ko mice compared with Wt mice. Although 
the difference in the duration of Lorr failed to reach 
significance (unpaired t test, P = 0.0691), the time to recovery 
(Wt: 101.1 ± 7.5 min, α3Ko: 53.8 ± 9.9 min) and the total 
Lorr score (Wt: 298.8 ± 23.6, α3Ko: 159.4 ± 27.3) were 
significantly lower in α3Ko mice (unpaired t test, P = 
0.0011 and P = 0.001, respectively). Similarly, the reduction 
in body temperature was smaller in α3Ko mice (two-way 
AnoVA with repeated measures of time: significant effect 
of time F(2,40) = 17.65, P < 0.0001; significant effect 
of genotype F(1,20), P = 0.0395 and significant time × 
genotype interaction F(2,40), P = 0.0008). Post hoc t tests 
with Bonferroni correction showed that the temperature 
difference was significant 90 min after injection (P < 0.01).
Pentobarbital
For pentobarbital two-way AnoVAs using drug dose and 
genotype as factors revealed main effects of drug and geno-
type on Lorr (drug F(2,32) = 160.92, P < 0.0001; geno-
type F(1,16) = 5.64, P = 0.304), on time to recovery (drug 
F(2,32) = 163.15, P < 0.0001; genotype F(1,16) = 5.51, P = 
0.0321) and on total Lorr score (drug F(2,32) = 158.06, 
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Table 1. Anesthetic Properties (Ketamine, Pentobarbital, Midazolam, Etomidate)
Drug Dose (mg/kg) Genotype n
Duration of  
LORR (min)
Time to  
Recovery (min)
Total LORR  
Score
LHWR  
(min)
Ketamine 150 WT 9 25.0 ± 2.4 36.1 ± 2.4 94.8 ± 5.6 0.0 ± 0.0
α3KO 7 26.7 ± 4.4 42.0 ± 5.3 110.1 ± 14.4 0.0 ± 0.0
200 WT 9 40.3 ± 4.4 61.7 ± 3.7 168.3 ± 10.3 0.0 ± 0.0
α3KO 7 34.1 ± 1.1 61.3 ± 3.0 161.6 ± 7.1 0.0 ± 0.0
250 WT 9 56.8 ± 5.9 83.0 ± 4.1 231.3 ± 11.7 0.0 ± 0.0
α3KO 7 62.6 ± 6.7 97.3 ± 5.8 269.6 ± 18.3 0.0 ± 0.0
Pentobarbital 40 WT 9 23.2 ± 3.7 26.3 ± 3.5 75.2 ± 10.6 0.0 ± 0.0
α3KO 9 34.8 ± 6.0 36.8 ± 5.7 107.6 ± 17.0 0.0 ± 0.0
50 WT 9 64.7 ± 3.6 65.9 ± 3.5 194.4 ± 10.6 0.0 ± 0.0
α3KO 9 85.0 ± 9.5 86.0 ± 9.5 255.2 ± 28.5 0.0 ± 0.0
60 WT 9 96.2 ± 3.6 98.2 ± 3.6 290.3 ± 10.7 0.0 ± 0.0
α3KO 9 126.8 ± 12.2* 129.1 ± 12.3* 382.1 ± 36.7* 25.0 ± 11.6
Midazolam 75 WT 11 73.5 ± 14.1 101.1 ± 7.5 298.8 ± 23.6 0.0 ± 0.0
α3KO 11 40.8 ± 9.4 53.8 ± 9.9** 159.4 ± 27.3*** 0.0 ± 0.0
Etomidate 30 WT 11 88.3 ± 4.3 91.1 ± 4.5 273.7 ± 10.3 0.0 ± 0.0
α3KO 11 72.7 ± 5.8* 77.2 ± 5.8 224.9 ± 17.6* 0.0 ± 0.0
Data represent the mean ± SEM. Duration of LORR, time to recovery and the global anesthetic score were significantly increased in 
α3KO mice compared with WT mice after 60 mg/kg pentobarbital (two-way ANOVA with repeated measures followed by post hoc t 
tests with Bonferroni correction). Time to recovery and the global anesthetic score were significantly decreased after 75 mg/kg mida-
zolam and the duration of LORR and the global anesthetic score were significantly decreased after 30 mg/kg etomidate in α3KO mice 
compared with WT mice (unpaired t test).
* P < 0.05, ** P < 0.01 and *** P < 0.001.
LHWR = loss of hind limb withdrawal reflex; LORR = loss of righting reflex; KO = knockout; WT = wild type.
Fig. 1. Effect of ketamine, pentobarbital, midazolam, and etomidate on (A) duration of LORR and (B) core body temperature. 
(A) Duration of LORR was significantly increased in α3KO mice by 60 mg/kg pentobarbital (repeated measures ANOVA followed 
by t tests with Bonferroni correction) and significantly decreased by 30 mg/kg etomidate (unpaired t test). (B) Repeated mea-
sures ANOVA showed a mean effect of genotype on core body temperature for 250 mg/kg ketamine, 75 mg/kg midazolam, and 
30 mg/kg etomidate. t Tests with Bonferroni correction revealed that the temperature decrease was more pronounced in α3KO 
mice compared with WT mice 60 min and 120 min after administration of ketamine and pentobarbital, respectively, and that the 
temperature decrease was less pronounced in α3KO mice compared with WT mice 90 min after administration of midazolam 
or etomidate. Data represent the mean ± SEM; *P < 0.05, **P < 0.01 and ***P < 0.001, n = 9 WT and n = 7 α3KO for ketamine; 
n = 9 for pentobarbital; n = 11 for etomidate and midazolam. KO = knockout; LORR = loss of righting reflex; WT = wild type.
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P < 0.0001, genotype F(1,16) = 5.63, P = 0.305). Further-
more, four out of nine α3Ko mice lost the hind limb with-
drawal reflex at the highest dose of pentobarbital (60 mg/
kg), whereas none of the Wt mice lost the reflex. This dif-
ference was not statistically significant (Fisher’s exact prob-
ability test: P = 0.0824). At the highest dose of pentobarbital 
(60 mg/kg), two-way AnoVA with repeated measures of 
time showed a significant effect of time F(3,48) = 27.19, 
P < 0.0001 but no effect of genotype F(1,16) = 3.60, P = 
0.0761). However, with respect to body temperature, there 
was a significant time x genotype interaction (F(3,48) = 5.56, 
P = 0.0023) and t tests with Bonferroni correction showed 
that body temperature was significantly lower in α3Ko mice 
120 min after injection (P < 0.001).
Anesthetic Endpoints with Ketamine and Medetomidine
Ketamine
There were no differences in duration of Lorr, time to 
recovery, total Lorr score or LHWr between Wt and 
α3Ko mice at any dose of ketamine, although two α3Ko 
mice died after administration of 150 and 250 mg/kg, 
respectively. However, the reduction in body temperature 
was significantly larger in α3Ko mice compared with Wt 
mice by 250 mg/kg ketamine (AnoVA with repeated mea-
sures of time: significant effect of time F(1,14) = 7.99 P = 
0.0134; significant effect of genotype F(1,14) = 7.99 P = 
0.025). Post hoc t tests with Bonferroni correction showed 
that body temperature was significantly different 60 min 
after injection (P < 0.05).
Medetomidine
Sedative Effects of Medetomidine
The sedative effects of the α2-adrenergic agonist 
medetomidine in α3Ko and Wt mice were assessed by 
measuring the locomotor activity in a novel open field over 
60 min following drug injection. The total distance traveled 
was decreased by medetomidine (30 or 60 µg/kg) (fig. 2A) 
but there were no differences between α3Ko and Wt mice 
(two-way AnoVA: significant effect of drug (F(2,48) = 
32.25, P < 0.0001) (insert in fig. 2A). Analysis with two-way 
AnoVA with repeated measures of 5-min time bins also 
did not reveal any difference between genotypes, although a 
general reduction in activity over time was observed in both 
genotypes (Vehicle: significant effect of time F(11,176) = 
32.41, P < 0.0001; 30 µg/kg: significant effect of time 
F(11,176) = 41.85, P < 0.0001; 60 µg/kg: significant effect 
of time F(11,176) = 47.54, P < 0.0001) (fig. 2A).
Hypnotic Effects of Medetomidine
The hypnotic effects of medetomidine in α3Ko and Wt 
mice were assessed 60 min after injection by rolling the 
mice on their side and noting the time to righting (fig. 2B). 
When righting did not occur within 30 min the observa-
tion was stopped. Data were analyzed by fitting standard 
least-squares mixed models with subject as a random effect. 
Drug dose and genotype were included as fixed effects. 
Effects were assessed by F tests based on the fitted regression 
models. This revealed a significant overall effect of genotype 
Fig. 2. Effects of medetomidine on locomotor activity (A), du-
ration of LORR (B) and body temperature (C) in α3KO and WT 
mice. (A) Locomotor activity was comparable in both geno-
types at all medetomidine doses over the whole 60 min time 
period (insert) and looking at 5-min time bins. (B) Duration of 
LORR was significantly increased in α3KO mice by 250 µg/
kg medetomidine compared with WT mice (Sheffé post hoc 
tests). (C) Body temperature was comparable between α3KO 
mice and WT mice. Data represent the mean ± SEM; n = 9 
per genotype. KO = knockout; LORR = loss of righting reflex; 
WT = wild type.
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(F[1,16] = 8.90, P = 0.0088) and dose (F[1,34] = 36.96, P < 
0.0001). Post hoc Sheffé tests showed that the Lorr was 
significantly increased in α3Ko mice (298 ± 192 s) com-
pared with Wt mice (6 ± 4 s) by 250 µg/kg medetomidine 
(P = 0.0098). At this dose, two of nine Wt mice lost the 
righting reflex (loss of righting reflex defined as inability to 
right within 10 s) in contrast to seven of nine α3Ko mice.
Hypothermic Effects of Medetomidine
The hypothermic effects of medetomidine in α3Ko and 
Wt mice were assessed by determining the rectal body tem-
perature immediately before drug or vehicle injection and 
every 30 min thereafter over a period of 120 min (fig. 2c).
The baseline body temperature before injection was 
increased in α3Ko mice compared with Wt mice in 
the groups that received vehicle (Wt = 38.29 ± 0.11°c, 
α3Ko = 39.01 ± 0.18°c, unpaired t test, P < 0.01) 
and 60 µg/kg medetomidine (Wt = 38.297 ± 0.15°c, 
α3Ko = 39.13 ± 0.17°c, unpaired t test, P < 0.01) in 
α3Ko mice (39.0 ± 0.2°c), but not in the group that 
received 120 µg/kg medetomidine (Wt = 38.82 ± 0.14°c, 
α3Ko = 38.97 ± 0.09°c, independent samples t test, P 
= 0.398). This precluded direct statistical analysis of the 
hypothermic effects of 60 µg/kg medetomidine. For the 
120µg/kg medetomidine dose, a genotype × time two-
way AnoVA did not reveal a significant genotype main 
Fig. 3. Schematic of genetic rescue of the α3KO in noradrenergic neurons. (A) α3KO and rescue alleles. The α3KO allele (top) 
has integrated the insertion-type gene targeting vector for single reciprocal recombination in its entirety.18 It carries an artificial 
exon (light green, 5*) flanked by loxP sites (red), targeting vector-derived homologous genomic sequences (light brown), and the 
plasmid backbone of the targeting vector (blue). Genomic sequences that were not included in the targeting vector are shown 
as dark brown. The most relevant feature is that the α3KO allele contains the endogenous exon 5 (dark green, 5) and an artificial 
exon 5 (light green, 5*), which results in mRNA degradation, which is the likely mechanism of the α3KO.18 In the rescue allele, 
elimination of the artificial exon by Cre-loxP-mediated recombination results in α3 mRNA (orange) being made and thus the 
expression of the α3 subunit being restored. (B) Exonic structure of predicted gene products from WT, α3KO, and rescue allele. 
Presence of the artificial exon 5, 5*, in the α3KO results in mRNA breakdown and thus a functional KO. The exonic structure of 
WT and rescue alleles is identical. KO = knockout; mRNA = messenger RNA; WT = wild type.
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effect or genotype × time interaction. In the entire study, 
a difference in baseline temperature was only present in 2 
of the 11 experiments performed in total with midazolam, 
pentobarbital, and ketamine. We therefore assume that 
extraneous undefined factors specific to the experiments 
with medetomidine are responsible for this baseline 
difference, and that overall Wt mice and α3Ko mice 
do not display a difference in baseline body temperature. 
When we analyzed the change in body temperature from 
baseline, we still did not obtain any significant differences 
between genotypes both for 60 µg/kg and for 120 µg/kg 
medetomidine (not shown).
Fig. 4. Localization and quantification of the α3KO in global rescue mice. (A) Generation of global rescue mice. An α3KO mouse 
(with artificial exon 5, the “STOP” signal) is bred with an EIIa-Cre mouse.19 Some of the offspring will carry both the α3KO allele 
and the EIIa-Cre transgene. This mouse is bred with a WT mouse to breed out the EIIa-Cre transgene (depicted by 2 sequential 
horizontal arrows) to confirm that the artificial exon 5 (the “STOP” signal) has been removed from the germline, so that the α3 
subunit is expected to be expressed in all cells in which it is naturally expressed. (B) Immunoperoxidase staining of perfusion-
fixed parasagittal brain sections: α3 subunit distribution pattern is equivalent in WT and global rescue mice. Representative 
sections from two WT and two global rescue mice are shown. (C) Left panel: Representative Western Blot: α3 subunit expres-
sion level is decreased in global rescue mice compared with WT mice. Right panel: Quantification of Western blot signal: signals 
were normalized to the α3 subunit signal at 10 μg protein in WT mice (100%). α3 subunit expression level in global rescue mice 
is 70 ± 7% of WT expression. Data represent the mean ± SEM of five experiments. KO = knockout; WT = wild type.
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Fig. 5. Recue of α3 expression in defined neuronal cell types. (A) An α3KO mouse is crossed with a DBH-iCre mouse to obtain 
DBH-iCre Rescue mice (in our studies hemizygous males) containing both the α3 knockout allele and the DBH-iCre transgene. 
The artificial exon 5 in the α3 KO allele functions as a “STOP” signal, resulting in messenger RNA degradation.18 In noradrenergic 
neurons of the Rescue mouse, this “STOP” signal is removed by cre-loxP-mediated recombination. Thus, in the Rescue mice, 
the α3 subunit is expressed only in the noradrenergic neurons. Similar considerations apply to the generation of the DAT-Rescue 
mice using the DAT-iCre transgene expressing iCre specifically in dopaminergic neurons. (B) Neuron-specific rescue of α3 sub-
unit expression in the locus coeruleus: Immunofluorescence double-labeling of the α3 subunit (red) and tyrosine hydroxylase 
(green) shows that the α3 subunit is highly expressed in the LC in WT mice. In α3KO mice expressing the iCre recombinase 
selectively in noradrenergic neurons (DBH-Rescue) α3 subunit expression is restricted to noradrenergic neurons. It is not detect-
able in the locus coeruleus of α3KO mice expressing the iCre recombinase exclusively in dopaminergic neurons (DAT-Rescue), 
nor in α3KO mice. Scale bar: 50 µm. (C) Neuron-specific rescue of α3 subunit expression in the SNpc: Immunofluorescence 
double-labeling of the α3 subunit (red) and tyrosine hydroxylase (green) shows that α3 subunit expression is found in dopami-
nergic neurons of the SNpc of WT mice and in α3KO mice expressing the iCre recombinase selectively in dopaminergic neurons 
(DAT-Rescue). It is not detectable in the SNpc of α3KO mice expressing the iCre recombinase selectively in noradrenergic neu-
rons (DBH-Rescue), nor in α3KO mice. Scale bar: 50 µm. DBH-iCre = dopamine β hydroxylase impoved Cre; DAT = dopamine 
transporter; WT = wild type; LC, locus coeruleus; SNpc = substantia nigra pars compacta.
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Generation of Mice Expressing the GABAA Receptor α3 
Subunit Exclusively in Noradrenergic Neurons
α3Ko mice used in this study have been generated using 
an insertion targeting strategy (fig. 1 in reference 18) with 
an insertion-type targeting vector containing exon 5 of 
the Gabra3 gene flanked by two loxP sites. This vector was 
inserted into the target locus in its entirety by single reciprocal 
recombination, resulting in a duplication of exon 5 (i.e., exon 
4 in fig. 1 in the study by yee et al.).18 The resulting α3Ko 
mice carry both an endogenous exon 5 and an artificial exon 
5* (5* in fig. 3A). This artificial exon 5* provides a “StoP” 
signal functionally disrupting the Gabra3 gene (fig. 3, A and 
B). We predicted that a cre-loxP-mediated excision of this 
loxP-flanked artificial exon 5* would functionally restore 
the Gabra3 gene. In a proof-of-principle experiment, α3Ko 
mice were crossed with EIIa-cre mice, which express the cre 
transgene at early embryonic stages19 (fig. 4A). As predicted, 
cre-loxP-mediated recombination resulted in the elimination 
of the loxP-flanked artificial exon 5*. Subsequently, the Ella-
cre transgene was bred out to ensure that the rescue of the 
α3 subunit had been present in the germline. These global 
rescue mice were examined for α3 subunit expression. Immu-
nohistochemical analysis revealed that α3 subunit expression 
is restored in these global rescue mice and the distribution 
pattern of α3 subunit expression is indistinguishable from 
Wt mice (fig. 4B). Western blot analysis showed that α3 
subunit expression levels in global rescue mice are 70 ± 7% 
compared with Wt mice (fig. 4c). Thus, the genomic rear-
rangement in the rescue allele, which includes the presence of 
a plasmid backbone, reduces the expression of the α3 subunit 
by approximately 30% without affecting its regional distribu-
tion. The precise mechanisms of this reduction are unknown.
Fig. 6. Effect of ketamine (139 mg/kg)/xylazine (21 mg/kg) on (A) duration of LORR and (B) core body temperature. (A) Duration 
of LORR was significantly increased in α3KO mice compared with WT mice, whereas mice expressing the α3 subunit exclusively 
in noradrenergic neurons (DBH-Rescue) and mice carrying the iCre transgene (DBH-iCre) did not differ from WT mice (one-way 
ANOVA followed by post hoc Dunnett t tests). (B) Body temperature was significantly lower in α3KO mice compared with WT 
mice 150 min and 180 min after injection. Body temperature in DBH-Rescue mice was significantly lower 180 min after injection 
compared with WT mice (two-way repeated measures ANOVA followed by post hoc t tests with Bonferroni correction). Data rep-
resent the mean ± SEM; ***P < 0.001 (α3KO compared with WT), *P < 0.05 (α3KO compared with WT), #P < 0.05 (DBH-Rescue 
compared with WT); n = 15 WT and DBH-iCre, n = 14 α3KO and DBH-Rescue. LORR = loss of righting reflex; WT = wild type; 
DBH = dopamine β hydroxylase; iCre = improved cre.
Table 2. Anesthetic Endpoints with Ketamine (139 mg/kg)/ Xylazine (21 mg/kg)
Genotype n Duration of LORR (min) Time to Recovery (min) Total LORR Score LHWR (min)
WT 15 144.7 ± 9.5 159.9 ± 9.7 466.3 ± 28.7 95.0 ± 7.8
DBH-iCre 15 136.9 ± 8.5 153.9 ± 9.4 448.3 ± 27.5 83.3 ± 5.0
α3KO 14 201.7 ± 11.9*** 218.2 ± 11.2*** 641.3 ± 33.9*** 137.1 ± 8.3***
DBH-Rescue 14 174.0 ± 9.8 201.9 ± 10.6* 588.4 ± 31.5* 113.2 ± 7.1
All anesthetic parameters were significantly increased in α3KO mice compared with WT. Time to recovery and total anesthetic score 
were significantly increased in DBH-Rescue mice compared with WT (one-way ANOVAs followed by post hoc Dunnett t tests). Data 
represent the mean ± SEM.
* P < 0.05 and *** P < 0.001 (compared with WT).
DBH = dopamine β hydroxylase, iCre = improved Cre; KO = knockout; LHWR = loss of hind limb withdrawal reflex; LORR = loss of right-
ing reflex; WT = wild type.
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In order to generate mice expressing the α3 subunit 
exclusively in noradrenergic neurons, mice carrying the α3 
knockout allele and a DBH-icre transgene (DBH-icre) 
were generated (fig. 5A). In addition, mice carrying the α3 
Ko allele and a DAt-icre transgene (DAt-icre) were gener-
ated to demonstrate the specificity of the rescue approach.
Immunofluorescence analysis confirmed that the α3 
subunit is exclusively expressed in noradrenergic neurons in 
α3Ko/DBH-icre (DBH-rescue) mice (fig. 5B), whereas it 
is exclusively expressed in dopaminergic neurons in α3Ko/
DAt-icre (DAt-rescue) mice (fig. 5c). Wt mice show 
intense expression of the α3 subunit on noradrenergic 
neurons of the locus coeruleus and on unidentified neurons 
in the proximity, whereas DBH-rescue mice express the α3 
subunit only on noradrenergic neurons (fig. 5B). α3 subunit 
expression is not detectable in α3Ko mice and DAt-rescue 
mice in this brain region (fig. 5B). to confirm the specificity 
of the rescue approach α3 subunit expression in DAt-rescue 
mice was examined further. In the dopaminergic neurons of 
the substantia nigra pars compacta the α3 subunit protein 
is absent in α3Ko and DBH-rescue mice, whereas high 
levels of α3 subunit expression are found in Wt mice, and 
expression is specifically restored in dopaminergic neurons 
in DAt-rescue mice (fig. 5c). In other brain regions where 
the α3 subunit is normally expressed, such as the cerebral 
cortex or the hippocampus but where no noradrenergic or 
dopaminergic neurons are present, no α3 subunit protein was 
detectable in DBH- or DAt-rescue mice (not shown). overall, 
these data demonstrate that the α3 subunit can be rescued 
specifically and to a large extent in noradrenergic neurons.
Anesthetic Endpoints with Ketamine/Xylazine and Rescue 
of the Phenotype in Mice Expressing the GABAA Receptor 
α3 Subunit Exclusively in Noradrenergic Neurons
In order to confirm the unexpected observation that 
ketamine/xylazine-induced anesthesia is significantly 
prolonged in α3Ko mice and to address the question whether 
α3 subunit–containing GABAA receptors on noradrenergic 
neurons modulate these anesthetic effects, we studied several 
anesthetic endpoints and the body temperature decrease 
during anesthesia in α3Ko mice, Wt mice, and DBH-
rescue mice (fig. 6 and table 2). to exclude the possibility that 
the icre transgene, which is also present in the DBH-rescue 
mice, causes any effects by itself (also referred to as potential 
“cre toxicity”), control mice expressing the icre transgene in 
noradrenergic neurons (DBH-icre) were included.
one-way AnoVA showed a significant effect of genotype 
for all anesthetic parameters: duration of Lorr (F[3,54] = 
8.81, P < 0.0001), time to recovery (F[3,54] = 9.52, 
P < 0.0001), total Lorr score (F[3,54] = 9.51, P < 
0.0001) and LHWr (F[3,54] = 10.76, P < 0.0001) (table 
2). Post hoc Dunnett tests revealed that α3Ko mice show 
significantly increased measures on all anesthetic param-
eters (Lorr, total Lorr score, LHWr, P < 0.001 and 
time to recovery P < 0.01) compared with Wt mice. In 
contrast, DBH-rescue mice showed an increase only in the 
time to recovery and the total Lorr score (P < 0.05) com-
pared with Wt mice; they were not different from Wts in 
terms of Lorr or LHWr times. In fact, the rescue mice 
were not different from either Wt or α3Ko mice on these 
parameters, suggesting that they rank in between the two 
genotypes, leading to a “partial rescue” of the α3Ko pheno-
type. The body temperature decrease caused by ketamine/
xylazine was analyzed by a two-way repeated measures 
AnoVA. A significant effect of genotype (F[3,54] = 2.85, 
P = 0.0456), significant effect of time (F[5,270] = 475.04, 
P < 0.0001) and a significant time × genotype interaction 
(F[15,270] = 5.69, P < 0.0001) were observed. Post hoc t 
tests with Bonferroni correction showed that the tempera-
ture was significantly lower in α3Ko mice 150 min (P < 
0.05) and 180 min (P < 0.001) after injection compared 
with Wt mice. DBH-rescue mice showed a significantly 
lower temperature only 180 min (P < 0.05) after injection 
compared with Wt mice. DBH-icre mice did not differ 
from Wt mice in any anesthetic endpoint or in the body 
temperature, indicating that the icre transgene itself has no 
effect on the parameters measured. overall, our results indi-
cate that the hypnotic phenotype present in α3Ko mice 
can be partially rescued by expression of the α3 subunit in 
noradrenergic neurons in DBH-rescue mice, whereas the 
hypothermic phenotype seems to be independent of the α3 
subunit in noradrenergic neurons.
Discussion
clinically used intravenous general anesthetics are a struc-
turally highly diverse class of drugs mediating their anes-
thetic effects through a variety of molecular targets.12 In 
this study, we evaluated the role of α3-containing GABAA 
receptors in the actions of intravenous anesthetics and found 
that although actions of GABAergic drugs like etomidate 
and midazolam are in part mediated by this receptor sub-
type, α3-containing GABAA receptors also constrain the 
actions of anesthetics that have partially (e.g., pentobarbi-
tal) or exclusively (ketamine/xylazine, medetomidine) non-
GABAergic targets. We also demonstrate that α3-containing 
GABAA receptors on noradrenergic neurons may constrain 
the hypnotic but not the hypothermic action of ketamine/
xylazine action.
Studies using mice carrying β2(n265S) or β3(n265M) 
point mutations rendering the mutated subunit insensitive 
to etomidate or etomidate and propofol, respectively, have 
revealed that GABAA receptors containing the β2 or β3 
subunits mediate the immobilizing (β3), hypnotic (β2 
and β3), and hypothermic actions (mainly β2, minor role 
of β3 shown for etomidate and pentobarbital, but not for 
propofol) of etomidate, propofol, and pentobarbital.30–32 In 
line with previous reports showing that mice lacking the β3 
subunit33 or the α1 subunit6 are less sensitive to the hypnotic 
effects of midazolam and etomidate, we found that α3Ko 
mice are likewise less sensitive to these agents, collectively 
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indicating that the α1, α3, and β3 subunits are involved in 
mediating the hypnotic response to GABAergic anesthetics. 
In contrast, α3Ko mice showed an increase in the sensitivity 
to the hypnotic, immobilizing, and hypothermic effects of 
pentobarbital. This is astonishing because GABAA receptors 
are a major target for pentobarbital.34 consistent with 
this assumption α1Ko mice6 and β3(n265M) point-
mutant mice32 are less sensitive to the hypnotic effects of 
pentobarbital; moreover, the immobilizing response to 
pentobarbital is completely absent in β3(n265M) point-
mutant mice.32 However, the GABAA receptor antagonist 
gabazine attenuates the hypnotic response to pentobarbital 
to a much lesser extent than the hypnotic response to 
muscimol and propofol, pointing to the potential relevance 
of non-GABAA receptor targets for pentobarbital actions.
35 
Furthermore, in contrast to etomidate some effects of 
pentobarbital such as respiratory depression are similar in 
Wt and β3(n265M) point-mutant mice.32 together with 
the fact that pentobarbital additionally acts on other drug 
targets such as nicotinic acetylcholine receptors, α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, 
kainate receptors, and glycine receptors36 it seems likely 
that at least some of the anesthetic effects of pentobarbital 
are mediated through non-GABAergic mechanisms. 
It is therefore possible that the increased sensitivity to 
pentobarbital in α3Ko mice results from alterations in 
non-GABAergic pathways such as the cholinergic system 
where α3 subunit expression has been described37 or 
potentially from up-regulation of non-GABAergic targets of 
pentobarbital or other compensatory mechanisms.
on the basis of the initial observation that ketamine/
xylazine anesthesia is prolonged in α3Ko mice and actions 
of such compounds would normally be expected to be 
unaltered in a GABAA receptor subunit Ko mouse, inves-
tigating the contribution of N-methyl-D-aspartate receptor 
antagonism and of α2-adrenergic receptor agonism to this 
phenomenon was a major goal in this study. We therefore 
examined the action of ketamine and of the α2-adrenergic 
agonist medetomidine. Medetomidine was chosen for two 
reasons: (1) Essential pharmacologically relevant data, for 
example, with respect to binding to α2-adrenergic recep-
tor subtypes were not available for xylazine, and (2) there 
is a significant body of experimental studies on the sedative, 
hypnotic, and hypothermic actions with medetomidine.38 
Strikingly, our studies revealed a clear dissociation between 
the sedative, hypothermic, and hypnotic effects induced 
by medetomidine. Although the sedative and hypothermic 
effects were indistinguishable between Wt and α3Ko mice, 
α3Ko mice were more sensitive to the hypnotic effects of 
medetomidine. However, it is interesting to note that the 
unspecific blockade of all GABAA receptor subtypes by 
the antagonist gabazine attenuates the hypnotic effects of 
medetomidine.16 This indicates that the hypnotic response 
to medetomidine may be modulated in different directions 
by different GABAA receptor subtypes. Interestingly, α3Ko 
mice did not differ from Wt mice in their hypnotic response 
to ketamine. However, the decrease in body temperature was 
more pronounced. Even though ketamine does not typi-
cally exhibit synergistic effects in combination with other 
anesthetic agents,39 our findings suggest that the increased 
sensitivity to the hypnotic effects of α2-adrenergic agents 
combined with the increased sensitivity to the hypothermic 
effects of ketamine might cause the significant phenotype 
observed in α3Ko mice in response to the drug combina-
tion ketamine/xylazine in a synergistic manner.
Another objective of this study was to evaluate whether 
α3-containing GABAA receptors on noradrenergic neurons 
constrain ketamine/xylazine action. For this purpose, we 
generated “rescue” mice expressing the α3 subunit exclusively 
in noradrenergic neurons. In these mice, the α3 subunit is 
expressed under the control of its endogenous promoter, 
thus limiting expression to cells in which expression occurs 
naturally. compared with the Wt allele the expression level 
of the rescue allele was approximately 70%. We assume that 
transcriptional processes may be partially disrupted due to 
the presence of foreign DnA (i.e., plasmid backbone of the 
targeting vector) in the allele. Presumably α3 expression 
levels in noradrenergic neurons will not reach Wt expression 
levels in the α3-DBH-rescue mice either, although this has 
not been formally examined. As a consequence a rescue of 
the α3Ko phenotype may not restore function to Wt levels. 
Indeed, this is what we observed in this study: the presence of 
α3-containing GABAA receptors on noradrenergic neurons 
partially abolishes the increased hypnotic and immobilizing 
actions of ketamine/xylazine observed in the α3Ko mice. 
The increased hypothermic actions, however, were not 
affected. This indicates that although noradrenergic neurons 
are involved in modulating the hypnotic and immobilizing 
actions of ketamine/xylazine, they may not be involved in 
modulating their hypothermic action.
our findings are consistent with a model in which the 
noradrenergic neurons naturally express both α2-adrenergic 
receptors and α3-containing GABAA receptors.
11 Activation 
of both receptors would be predicted to decrease the activity 
of the noradrenergic neurons. Similar to previous findings in 
the reticular nucleus of the thalamus,40 currently unexplained 
compensations to preserve inhibitory function may be present 
in α3Ko mice. At the same time, increased sensitivity to α2-
adrenergic agonists might occur in α3Ko mice to compensate 
for the lack of GABAergic inhibition and designed to keep the 
inhibitory modulation of these neurons constant. This would 
explain why the hypnotic and hypothermic actions of com-
pounds such as midazolam and etomidate, which act mainly 
or exclusively via GABAA receptors without any effect on α2-
adrenergic receptors, are reduced in the α3Ko mice, whereas 
the hypnotic action of medetomidine, which has no effect on 
GABAA receptors, is increased.
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